Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Summit Therapeutics hails Rare Disease Day

Tuesday, February 28, 2017 7:35
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summit Therapeutics PLC (NASDAQ: SMMT LON:SUMM) has hailed the tenth annual Rare Disease Day, 28 February 2017.

The drug developer has trials underway for treatments for Duchenne muscular dystrophy and Clostridium difficile infection.

Glyn Edwards, Summit’s chief executive, said:  ”We applaud EURORDIS, the organisation representing rare disease patients in Europe, for bringing an annual spotlight to the plight of millions of people affected by rare diseases and in this year, recognising the immense impact that research is having and will continue to have for those living with rare diseases.”

“In the European Union a rare disease is defined as one that affects fewer than 5 in 10,000 of the general population, while in the United States, it is defined as a disease that affects fewer than 200,000 people. 

“There are between 6,000 and 8,000 known rare diseases with around five new rare diseases described in the literature each week.

“Rare diseases are often chronic and life threatening and include rare conditions, such as childhood cancers, and some other well-known conditions including cystic fibrosis and DMD.”

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/173931/summit-therapeutics-hails-rare-disease-day-173931.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.